UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology

Meghan J. Price,Annee D. Nguyen,Jovita K. Byemerwa,Jasmine Flowers,César D. Baëta,C. Rory Goodwin
DOI: https://doi.org/10.18632/oncotarget.28514
2023-09-28
Oncotarget
Abstract:UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.
What problem does this paper attempt to address?